(Q36631654)

15 August 2017

1 reference

title

Drug Insight: new drugs in development for Parkinson's disease (English)

1 reference

15 August 2017

1 reference

3

Alfredo Berardelli

1 reference

15 August 2017

2

Giovanni Fabbrini

1 reference

15 August 2017

1

Carlo Colosimo

1 reference

15 August 2017

1 November 2006

1 reference

Nature Clinical Practice Neurology

15 August 2017

1 reference

15 August 2017

2

1 reference

15 August 2017

11

1 reference

15 August 2017

600-610

1 reference

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

15 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Motor fluctuations in Parkinson's disease: pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Pathophysiology of levodopa-induced dyskinesia: potential for new therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Cognitive function in Parkinson's disease: From description to theory

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Treatments for dysarthria in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Psychosis in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Epidemiology and clinical features of sleep disorders in extrapyramidal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Molecular Pathways of Neurodegeneration in Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Dopaminergic neurons degenerate by apoptosis in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Creatine and cyclocreatine attenuate MPTP neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Postmenopausal estrogen use affects risk for Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Estrogen as neuroprotectant of nigrostriatal dopaminergic system: laboratory and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

GM1 ganglioside in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Gangliosides. Their role in clinical neurology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Neuroimmunophilin ligands in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Neuroimmunophilins: a novel drug therapy for the reversal of neurodegenerative disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

The immunophilin ligand GPI-1046 does not have neuroregenerative effects in MPTP-treated monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Inhibition of microglial inflammation by the MLK inhibitor CEP-1347.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

The effects of a selective dopamine D2 receptor agonist on behavioral and pathological outcome in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated squirrel monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

A controlled trial of rotigotine monotherapy in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Improvement of motor function in early Parkinson disease by safinamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

A double-blind crossover, placebo-controlled study of the adenosine A2A antagonist theophylline in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Noradrenergic drugs for levodopa-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Distribution of alpha 2-adrenergic receptor subtype gene expression in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

A role for striatal beta-adrenergic receptors in the regulation of dopamine release.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

The effects of yohimbine on exploratory and locomotor behaviour are attributable to its effects at noradrenaline and not at benzodiazepine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Presymptomatic compensation in Parkinson's disease is not dopamine-mediated

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Levetiracetam as add-on therapy in generalised epilepsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

7 January 2021

Clinical usefulness of apomorphine in movement disorders.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

7 January 2021

Selegiline slows the progression of the symptoms of Parkinson disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

7 January 2021

The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

7 January 2021

The Clinical Efficacy of Oral Levodopa Methyl Ester Solution in Reversing Afternoon “Off” Periods in Parkinsonʼs Disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

7 January 2021

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

7 January 2021

Transdermal lisuride delivery in the treatment of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

7 January 2021

Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

7 January 2021

Theophylline increases "on" time in advanced parkinsonian patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

7 January 2021

Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

7 January 2021

Depression in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

7 January 2021

Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FNCPNEURO0340

7 January 2021

Identifiers

DOI

10.1038/NCPNEURO0340

1 reference

15 August 2017

1 reference

PubMed ID

17057747